Literature DB >> 7757996

C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?

M Underwood1, J Bartlett, J Reeves, D S Gardiner, R Scott, T Cooke.   

Abstract

C-erbB-2 gene amplification and protein overexpression have been implicated as prognostic markers for patients with recurrent progressive bladder tumors. This event has been investigated as a potential diagnostic indicator in archival samples of transitional cell carcinoma of the bladder. Two hundred thirty-six bladder tumors from 89 patients with recurrent disease (mean follow-up, 4 years), 20 tumors from patients with no evidence of bladder tumor recurrence (mean follow-up, 7 years) and 10 normal bladder controls (patients with no history of transitional cell carcinoma) were studied. A differential PCR was used to provide a semiquantitative estimate of C-erbB-2 gene amplification. Protein overexpression was assessed immunohistochemically. Sixteen of 89 patients with recurrent disease had evidence of C-erbB-2 gene amplification. No C-erbB-2 gene amplification was seen in the nonrecurrent tumors or normal bladder controls. Of the 89 patients with recurrent bladder tumors, 43 had evidence of progressive disease, and of these, 14 patients exhibited C-erbB-2 gene amplification, indicating a strong association with gene amplification and progressive disease (P < 0.0005). Gene amplification in these patients was seen only after disease progression had occurred. Protein overexpression was seen in 50% of patients with recurrent and 45% of patients with nonrecurrent disease. No protein overexpression was seen in normal controls. Protein overexpression could not be linked to disease progression. C-erbB-2 gene amplification and protein overexpression were of predictive value in multivariate analysis for overall bladder cancer death; however stage and grade remained the most important independent prognostic variables. C-erbB-2 gene amplification and protein overexpression were of no value as independent markers for the prediction of disease recurrence or progression. It appears from these results that the role of C-erbB-2 as a diagnostic marker may far outweigh its usefulness as a prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757996

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

Review 2.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

Review 3.  Role of anti-Her-2 therapy in bladder carcinoma.

Authors:  Alvaro Pinto Marín; Enrique Espinosa Arranz; Andrés Redondo Sánchez; Pilar Zamora Auñón; Manuel González Barón
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

4.  [Tumors of the urinary system. Current and old problems].

Authors:  S Minner; G Sauter
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

5.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Authors:  M Laé; J Couturier; S Oudard; F Radvanyi; P Beuzeboc; A Vieillefond
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

6.  Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.

Authors:  Laleh Ehsani; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.

Authors:  Surendra B Kolla; Amlesh Seth; Manoj K Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Rajeev Kumar
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 8.  Multimodal management of muscle-invasive bladder cancer.

Authors:  Jong Chul Park; Deborah E Citrin; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Probl Cancer       Date:  2014-06-23       Impact factor: 3.187

9.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.